Bilişsel

9-Me-BC (9-Methyl-beta-carboline) is a synthetic beta-carboline derivative that has attracted significant attention in the nootropic community for its apparent ability to promote dopaminergic neuron growth, differentiation, and restoration. Unlike conventional dopaminergic drugs that manipulate existing neurotransmitter levels through reuptake inhibition or receptor agonism, 9-Me-BC appears to act at a more fundamental level by upregulating tyrosine hydroxylase expression, stimulating neurotrophic factors, and promoting the outgrowth of dopaminergic neurites. This neurorestorative profile has made it a subject of interest in Parkinson's disease research, where the degeneration of dopaminergic neurons in the substantia nigra is the core pathological feature. In the nootropic and performance-enhancement communities, 9-Me-BC has gained popularity as a tool for 'dopamine repair' -- the attempt to restore normal dopaminergic function after periods of stimulant abuse, chronic stress, or hormonal suppression (such as after SARM cycles). However, the compound carries a critical safety concern: 9-Me-BC is photosensitizing and potentially phototoxic, meaning that UV exposure during use can cause severe skin reactions and, more seriously, DNA damage in skin cells. All available research is limited to animal models and in-vitro cell culture studies, with no human clinical trials conducted to date.

Enhanced derivative of Selank with improved stability, blood-brain barrier penetration, and extended half-life compared to parent compound. Parent compound Selank approved in Russia since early 2000s.

Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement, neuroprotection, and neuroplasticity.

Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status.

Bromantane (Ladasten) is a synthetic adamantane derivative developed in Russia during the 1980s as part of a military research program aimed at improving soldiers' physical and mental performance under extreme conditions. It was officially registered in Russia in 2002 as an anxiolytic and actoprotector -- a pharmacological class defined by the ability to enhance physical work capacity and mental performance under stressful conditions without the hyperactivation or crash associated with traditional stimulants. Unlike amphetamines, methylphenidate, or modafinil, bromantane does not directly block reuptake or trigger release of monoamines. Instead, it upregulates the gene expression of key enzymes in the dopamine biosynthetic pathway, producing a sustained, physiological increase in dopamine availability. This mechanism gives it a uniquely smooth, non-depleting profile that has made it increasingly popular in the international nootropic community for sustained cognitive energy, motivation, and stress resilience.

Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.

Cortagen is a Khavinson bioregulator tetrapeptide (AEDP) with primary effects on the brain and central nervous system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it regulates inflammatory responses in the nervous system, restores balance between pro- and anti-oxidative processes, and stimulates interleukin-2 expression. Research shows potential benefits for ischemic brain injury recovery, nerve regeneration, and reducing autoimmune reactions affecting the CNS.

Endogenous cyclic dipeptide found in plasma, breast milk, and cerebrospinal fluid. Functions as metabolite of IGF-1, regulating its bioavailability through competitive binding to IGFBP-3. Demonstrates neuroprotective, cognitive-enhancing, and cardioprotective properties supported by clinical trials.

Dihexa is a synthetic oligopeptide derived from angiotensin IV that potently enhances cognitive function by promoting synaptogenesis. It is 10 million times more potent than BDNF at promoting synapse formation through HGF/c-Met receptor activation.

DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health.

DSIP is a naturally occurring nonapeptide discovered in 1974 in rabbit brain. Originally isolated for sleep-promoting properties, it has diverse neuromodulatory effects including stress reduction, pain modulation, and endocrine regulation without traditional sedative effects.

FGL is a synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). It mimics the interaction between NCAM and fibroblast growth factor receptor 1 (FGFR1), activating downstream signaling cascades that promote synaptic plasticity, neurogenesis, and neuroprotection. Research has primarily been conducted in animal models, where FGL has shown promise for cognitive enhancement, stroke recovery, and neurodegenerative disease models.

Humanin was the first mitochondria-derived peptide (MDP) discovered, originally cloned from the occipital lobe of an Alzheimer's patient. It is a 24-amino acid peptide encoded from the 16S rRNA region of mitochondrial DNA with potent neuroprotective, cytoprotective, and anti-apoptotic properties. Research shows humanin levels decline with age but remain stable in long-lived species like naked mole-rats, and offspring of centenarians have significantly higher humanin levels.

IllumiNeuro is a cognitive enhancement peptide blend combining four nootropic peptides: PE-22-28 (neuritogenic), Pinealon (pineal bioregulator), NA-Semax Amidate (neuroprotective/cognitive), and NA-Selank Amidate (anxiolytic/cognitive). The standard formulation contains 48mg total (PE-22-28 10mg + Pinealon 10mg + NA-Semax 20mg + NA-Selank 8mg). This blend targets multiple neurological pathways for comprehensive cognitive support, though no clinical studies exist on this specific four-peptide combination.

Methylene blue (methylthioninium chloride) is one of the oldest synthetic drugs in medicine, first synthesized in 1876 and originally used as a textile dye before its medicinal properties were discovered. It is FDA-approved for the treatment of methemoglobinemia, a condition in which hemoglobin is unable to carry oxygen effectively. Beyond its approved indication, methylene blue has attracted significant interest as a mitochondrial-enhancing nootropic and neuroprotective agent. At low doses (0.5-2 mg/kg), it acts as an alternative electron carrier in the mitochondrial electron transport chain, bypassing Complex I and Complex III to donate electrons directly to Complex IV (cytochrome c oxidase). This enhances mitochondrial respiration, increases ATP production, and reduces the generation of reactive oxygen species. Methylene blue also inhibits monoamine oxidase (MAO-A), nitric oxide synthase, and has demonstrated anti-inflammatory, antimalarial, and antimicrobial properties. Its neuroprotective potential has been explored in Alzheimer's disease, Parkinson's disease, and traumatic brain injury models.

Modafinil is a wakefulness-promoting agent (eugeroic) originally developed in France in the late 1970s and approved by the FDA in 1998. It is prescribed for the treatment of excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea. Unlike traditional psychostimulants such as amphetamines, modafinil produces wakefulness and alertness with a markedly lower abuse potential and a more favorable side effect profile. It has become one of the most widely used compounds in the nootropic and biohacker community due to its ability to sustain focus, reduce fatigue, and enhance executive function during extended periods of cognitive demand. Armodafinil, the R-enantiomer, is marketed separately under the brand name Nuvigil and offers a longer duration of action at a lower dose.

Enhanced and stabilized version of Russian nootropic Semax with superior stability, extended half-life, and enhanced bioavailability through acetylation and amidation modifications.

NA-Selank Amidate is an enhanced version of Selank, the anxiolytic nootropic peptide developed at Russia's Institute of Molecular Genetics. The N-acetyl group improves blood-brain barrier penetration and creates more stable metabolites, while the C-terminal amidation further enhances metabolic stability and receptor binding. Unlike benzodiazepines, it provides anxiety relief without sedation, dependency, or cognitive impairment.

Noopept (GVS-111, omberacetam) is a synthetic nootropic dipeptide developed at the Russian Academy of Medical Sciences in the 1990s. It is approved and marketed in Russia and several CIS countries for cognitive impairment of various origins, including post-traumatic and cerebrovascular conditions. Structurally related to the racetam family, Noopept is not technically a racetam itself but is often grouped with them due to a shared mechanism of action involving modulation of glutamatergic neurotransmission. Its standout characteristic is extraordinary potency -- roughly 1000 times more potent than piracetam by weight -- which allows effective dosing in the 10-30 mg range rather than the multi-gram doses required by piracetam. Noopept is rapidly absorbed and converted to its primary active metabolite, cycloprolylglycine, an endogenous neuropeptide that mediates much of the compound's sustained cognitive and neuroprotective activity.

Oxiracetam (ISF-2522) is a synthetic nootropic compound belonging to the racetam family, first developed in the 1970s by ICF, an Italian pharmaceutical company. It is a hydroxylated derivative of piracetam and is approved as a prescription medication in Italy and several other European and Asian countries for the treatment of cognitive decline associated with dementia and organic brain syndromes. Among the racetams, oxiracetam is widely regarded as the most effective for logical reasoning, mathematical thinking, and technical work -- a reputation that distinguishes it from piracetam, which users more commonly associate with verbal fluency and creative thinking. Oxiracetam is well absorbed orally with high bioavailability, is not significantly metabolized by the liver, and is excreted largely unchanged by the kidneys, giving it a clean pharmacokinetic profile with minimal drug-drug interaction potential.

Nine-amino-acid peptide hormone produced in hypothalamus, released by posterior pituitary. Functions in social bonding, trust, empathy, reproduction, childbirth, lactation. FDA-approved synthetically for labor induction and postpartum hemorrhage.

P21 is a nootropic peptide derived from ciliary neurotrophic factor (CNTF) that enhances neurogenesis and cognitive function. It contains an adamantane moiety that enables blood-brain barrier penetration. Research shows it increases BDNF expression, inhibits LIF signaling to promote neurogenesis, and reduces tau and amyloid pathology in Alzheimer's disease models. Remarkably, P21 can boost neurogenesis in diseased brains above levels seen in healthy untreated brains.

Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects.

Phenibut (beta-phenyl-gamma-aminobutyric acid) is a synthetic GABA analog developed in the Soviet Union in the 1960s. It was designed to cross the blood-brain barrier, which GABA itself cannot do efficiently, by adding a phenyl ring to the GABA molecule. Phenibut has been prescribed in Russia and several former Soviet states since the 1960s for the treatment of anxiety, insomnia, post-traumatic stress disorder, vestibular disorders, and stuttering. It was famously included in the medical kit of Soviet cosmonauts for its calming effects without impairing cognitive performance. Phenibut is NOT approved by the FDA, EMA, or any Western regulatory agency as a pharmaceutical drug. In the United States, Australia, and parts of Europe, it has been sold as a dietary supplement or nootropic, though several countries have moved to restrict or ban its sale due to growing reports of dependence, withdrawal, and adverse events. The addiction and dependence potential of phenibut is HIGH, and tolerance develops rapidly with repeated use. This compound should be treated with the same caution as benzodiazepines or other GABAergic drugs.

Phenylpiracetam (also known as Phenotropil, Carphedon, or Fonturacetam) is a phenylated derivative of piracetam developed in Russia in 1983, originally for Soviet cosmonauts to enhance cognitive function, physical stamina, and cold tolerance during space missions. The addition of a phenyl group to piracetam's pyrrolidone nucleus fundamentally changes the compound's pharmacological profile -- it crosses the blood-brain barrier more readily, has significantly greater affinity for multiple neurotransmitter systems, and exhibits pronounced psychostimulant and physical performance-enhancing properties absent in piracetam. Phenylpiracetam was approved and marketed in Russia as Phenotropil for cognitive impairment, asthenia, and convulsive disorders until its manufacturer ceased production. It gained notoriety in the sporting world after the World Anti-Doping Agency (WADA) added it to the prohibited substances list following its detection in several Olympic athletes, confirming its reputation as a legitimate performance enhancer. One of its most distinctive properties is the enhancement of cold tolerance, a trait that directly reflects its origins as a cosmonaut support compound and has been demonstrated in animal models of hypothermia.

Developed in Russia, Pinealon demonstrates unique DNA-interaction for neuroprotection and cognitive enhancement. Benefits traumatic brain injury recovery and age-related cognitive decline with excellent safety profile.

Selank is a synthetic heptapeptide analog of the naturally occurring immune peptide tuftsin, developed by the Russian Academy of Sciences. It provides anxiolytic effects comparable to benzodiazepines but without sedation, amnesia, tolerance, or withdrawal.

Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) fragment 4-10, originally developed in Russia for stroke recovery. It achieves enhanced CNS penetration through direct transport via olfactory epithelium and trigeminal nerves, bypassing the blood-brain barrier.

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions.